
Moritz Fürstenau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5550745/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
2	Efficacy of Mefloquine Intermittent Preventive Treatment in Pregnancy Against Schistosoma haematobium Infection in Gabon: A Nested Randomized Controlled Assessor-Blinded Clinical Trial. Clinical Infectious Diseases, 2013, 56, e68-e75.	5.8	52
3	The CLL12 trial: ibrutinib vs placebo in treatment-naÃ⁻ve, early-stage chronic lymphocytic leukemia. Blood, 2022, 139, 177-187.	1.4	40
4	COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 2020, 34, 2225-2229.	7.2	39
5	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. HemaSphere, 2019, 3, e287.	2.7	33
6	Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 2022, 139, 1318-1329.	1.4	30
7	Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica, 2019, 104, 2144-2154.	3.5	20
8	Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. Cancers, 2021, 13, 1336.	3.7	20
9	Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 2018, 132, 694-694.	1.4	16
10	How to approach CLL in clinical practice. Hematological Oncology, 2019, 37, 38-42.	1.7	15
11	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. Haematologica, 2021, 106, 543-554.	3.5	12
12	COVIDâ€19 complicated by parainfluenza coâ€infection in a patient with chronic lymphocytic leukemia. European Journal of Haematology, 2020, 105, 508-511.	2.2	10
13	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2021, 137, 2267-2271.	1.4	10
14	Invasive Aspergillosis in Patients Treated With Ibrutinib. HemaSphere, 2020, 4, e309.	2.7	9
15	Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clinical Cancer Research, 2022, 28, 4203-4211.	7.0	9
16	Durable remissions following combined targeted therapy in patients with CLL harboring <i>TP53</i> deletions and/or mutations. Blood, 2021, 138, 1805-1816.	1.4	7
17	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 2020, 34, 1177-1181.	7.2	6
18	Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia, 2020, 34, 924-928.	7.2	4

#	Article	IF	CITATIONS
19	Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia, 2022, 36, 2125-2128.	7.2	4
20	Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. American Journal of Hematology, 2021, 96, E457-E460.	4.1	3
21	Relapsed disease and aspects of undetectable MRD and treatment discontinuation. Hematology American Society of Hematology Education Program, 2019, 2019, 482-489.	2.5	2
22	Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4430-4430.	1.4	1